HSV2

Hey Jane Launches Personalized Reproductive and Sexual Health Virtual Services Beyond Abortion Care

Retrieved on: 
Wednesday, August 9, 2023
Health, Telemedicine, Virtual Medicine, WHNP-BC, Urinary tract infection, WA, Bacterial vaginosis, Prescription, APRN, Simplex, DNP, Vaginitis, Abortion, CO, Patient, HSV1, RN, Knowledge, HSV2, FDA, Candidiasis, Birth control, MD

Hey Jane, the leading virtual abortion provider, announced the expansion of its patient-centered reproductive and sexual health care services.

Key Points: 
  • Hey Jane, the leading virtual abortion provider, announced the expansion of its patient-centered reproductive and sexual health care services.
  • As the most trusted virtual provider of medication abortion care, patients already come to Hey Jane with one of their most sensitive health care needs.
  • “When we started Hey Jane, we were addressing one of the most critical health care needs: abortion,” said Kiki Freedman, co-founder and CEO of Hey Jane.
  • To learn more about Hey Jane's expanded services and its commitment to making reproductive and sexual health care accessible to as many people as possible, please visit heyjane.com.

QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency

Retrieved on: 
Monday, August 15, 2022
Health, Infectious Diseases, Clinical Trials, Research, Pharmaceutical, Science, U.S. Securities and Exchange Commission, Â, Monkeypox, Union, Public health, Laboratory, World Health Organization, Budget, VZV, NYSE, Senior, HSV2, Growth, SEC, Research, Life, Government, Blood, European, DNA, COVID-19, Infection, Urinary tract infection, QIAGEN, List of life sciences, HH6, RNA, RUO, Gold standard (test), Herpes labialis, Enterovirus, Knowledge, WHO, World, Automation, QGEN, Meningitis, Protein, Monkeypox virus, Molecular diagnostics, PCR, Solution, LDT, HSV1, Vaccine, Pharmaceutical industry, Insight

The new panel currently for research use only (RUO) comes in cartridge form to run on QIAGENs QIAstat-Dx automated syndromic testing devices.

Key Points: 
  • The new panel currently for research use only (RUO) comes in cartridge form to run on QIAGENs QIAstat-Dx automated syndromic testing devices.
  • Currently the worlds only syndromic test for the pathogen, the panel will prove to be crucial for detecting and then combatting the spread of monkeypox around the globe.
  • The panels RUO-status means it currently can only be used for the surveillance not screening or diagnosing of monkeypox cases.
  • QIAGEN teams around the world are working with healthcare authorities to support testing for the monkeypox virus outbreak.

United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University Partner on World's First Long-acting Herpes Treatment UB-621

Retrieved on: 
Monday, October 18, 2021
CQD, Cell, University of Washington Department of Global Health, National Cheng Kung University, Coinfection, National Institute, HSV1, Department, National Institute of Allergy and Infectious Diseases, Simplex, Woman, Half-life, Herpes simplex, Biopharma LLC, HIV, DNA, University of Duisburg-Essen, Patient, HSV, Infection, Recurrence, University, Genital herpes, HSV2, Immunology, Dartmouth College, Research, Partnership, Quality of life, University of Duisburg, Vaccine, Pharmaceutical industry

TAIPEI, Oct. 18, 2021 /PRNewswire/ -- United BioPharma announced today that Shanghai Public Health Clinical Centre and Cheng Kung University's Department of Microbiology and Immunology have joined United BioPharma's fight against the global herpes endemic. Together with United BioPharma, the two institutions will test the effectiveness of UB-621, a best-in-class long-acting treatment for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and HSV2) in preparation for phase II trials in the United States and China.

Key Points: 
  • TAIPEI, Oct. 18, 2021 /PRNewswire/ -- United BioPharma announced today that Shanghai Public Health Clinical Centre and Cheng Kung University's Department of Microbiology and Immunology have joined United BioPharma's fight against the global herpes endemic.
  • The latest additions to the partnership will work with existing partners to test the neutralizing activity of UB-621 to the HSV clinical isolates in mainland China and Taiwan.
  • "We know UB-621 can neutralize over 40 HSV isolates from Asia, the United States and Germany.
  • With Cheng Kung University and the Shanghai Public Health Clinical Centre's support, we hope to demonstrate further the capability of UB-621 as we move to phase two trials," addedDr.

United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University Partner on World's First Long-acting Herpes Treatment UB-621

Retrieved on: 
Monday, October 18, 2021
CQD, Cell, University of Washington Department of Global Health, National Cheng Kung University, Coinfection, National Institute, HSV1, Department, National Institute of Allergy and Infectious Diseases, Simplex, Woman, Half-life, Herpes simplex, Multimedia, Biopharma LLC, HIV, DNA, University of Duisburg-Essen, Patient, HSV, Infection, Recurrence, University, Genital herpes, HSV2, Immunology, Dartmouth College, Research, Partnership, Quality of life, University of Duisburg, Vaccine, Pharmaceutical industry

TAIPEI, Oct. 18, 2021 /PRNewswire/ -- United BioPharma announced today that Shanghai Public Health Clinical Centre and Cheng Kung University's Department of Microbiology and Immunology have joined United BioPharma's fight against the global herpes endemic.

Key Points: 
  • TAIPEI, Oct. 18, 2021 /PRNewswire/ -- United BioPharma announced today that Shanghai Public Health Clinical Centre and Cheng Kung University's Department of Microbiology and Immunology have joined United BioPharma's fight against the global herpes endemic.
  • The latest additions to the partnership will work with existing partners to test the neutralizing activity of UB-621 to the HSV clinical isolates in mainland China and Taiwan.
  • "We know UB-621 can neutralize over 40 HSV isolates from Asia, the United States and Germany.
  • With Cheng Kung University and the Shanghai Public Health Clinical Centre's support, we hope to demonstrate further the capability of UB-621 as we move to phase two trials," addedDr.